What is HER2-mutant NSCLC?

HER2 is a protein that lives on a cell’s surface and can be used as a target for certain cancer medicines

HER2 can be present on normal cells; however, mutations can develop, which most commonly occur at the base of the HER2 protein inside the cell

HER2 mutations can cause abnormal cell activity, promoting the growth of cancer cells

2-4% of people with NSCLC have HER2 mutations. If test results show that your NSCLC has a certain HER2 mutation, ENHERTU might be right for you
What is ENHERTU?
ENHERTU is a prescription medicine used to treat adults who have non-small cell lung cancer (NSCLC) that has a certain mutation in the HER2 gene and cannot be removed by surgery or has spread to other parts of your body (metastatic), and who have received a prior treatment. Your healthcare provider will perform a test to make sure ENHERTU is right for you.
- ENHERTU was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. ENHERTU is still being studied to confirm these results.
It is not known if ENHERTU is safe and effective in children.
How is ENHERTU thought to work?
As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies.

of an antibody with
chemotherapy attached

ENHERTU targets and
attaches to HER2
on the cancer cell

the cancer cell and the
chemotherapy is released

of ENHERTU helps
destroy the cancer cell
as well as other cells nearby
Although ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells.
ENHERTU may not work for everyone.
How will I receive ENHERTU?
ENHERTU is given as an intravenous (IV) infusion. You will receive an ENHERTU infusion once every 3 weeks, either at your oncologist’s office or at a nearby infusion center.

Your healthcare provider will give you medicines before your infusion to help prevent nausea and vomiting

The first ENHERTU infusion will take about 90 minutes so the healthcare provider can monitor any potential reactions

Future ENHERTU infusions should take about 30 minutes, if your first infusion was well tolerated
If you miss a planned dose of ENHERTU, call your healthcare provider right away to schedule an appointment. Do not wait until the next planned treatment cycle.

Learn more about ENHERTU,
including Important Safety Information

HER2, human epidermal growth factor receptor 2; NSCLC, non-small cell lung cancer.